Definium Therapeutics’ shares rise sharply after the company reports late-stage trial results for an experimental depression treatment based on LSD. Bloomberg and the Post both say the stock jumps by roughly half to more than half on Monday, with Definium shares rallying as much as about 60% (Bloomberg) and around 55% (Post) to levels not seen for more than four years.
The company’s late-stage study focuses on major depressive disorder. Definium says a single dose of its LSD-based pill leads to significant symptom reduction compared with placebo. Both sources report that patients receiving the experimental treatment record lower scores on a standard depression rating scale after six weeks.
While the Post describes the results as strong and notes the magnitude of the share move, both outlets attribute the market reaction to the trial’s reported efficacy and the company’s characterization of the findings as notable. The reports do not provide additional details in the excerpts about safety outcomes, sample size, or regulatory next steps.
